Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 393

1.

A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.

Speransky S, Serafini P, Caroli J, Bicciato S, Lippman ME, Bishopric NH.

Breast Cancer Res Treat. 2019 Jul;176(2):271-289. doi: 10.1007/s10549-019-05174-3. Epub 2019 Apr 20.

2.

RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer.

Goka ET, Chaturvedi P, Lopez DTM, Garza A, Lippman ME.

Mol Cancer Ther. 2019 May;18(5):957-968. doi: 10.1158/1535-7163.MCT-18-0955. Epub 2019 Mar 29.

PMID:
30926638
3.

The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment.

Taub CJ, Lippman ME, Hudson BI, Blomberg BB, Diaz A, Fisher HM, Nahin ER, Lechner SC, Kwak T, Hwang GH, Antoni MH.

Cancer. 2019 May 15;125(10):1717-1725. doi: 10.1002/cncr.31965. Epub 2019 Jan 11.

PMID:
30633331
4.

Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity.

Surnar B, Kolishetti N, Basu U, Ahmad A, Goka E, Marples B, Kolb D, Lippman ME, Dhar S.

Biochemistry. 2018 Nov 20;57(46):6500-6513. doi: 10.1021/acs.biochem.8b00712. Epub 2018 Nov 7.

PMID:
30281285
5.

Endocrine Adjuvant Therapy for Localized Breast Cancer.

Lippman ME.

N Engl J Med. 2018 Jul 12;379(2):193-194. doi: 10.1056/NEJMe1806130. Epub 2018 Jun 4. No abstract available.

PMID:
29863436
6.

Targeting RAGE Signaling in Inflammatory Disease.

Hudson BI, Lippman ME.

Annu Rev Med. 2018 Jan 29;69:349-364. doi: 10.1146/annurev-med-041316-085215. Epub 2017 Nov 6.

PMID:
29106804
7.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

8.

Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.

Miller P, Kidwell KM, Thomas D, Sabel M, Rae JM, Hayes DF, Hudson BI, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2017 Nov;166(1):85-94. doi: 10.1007/s10549-017-4366-6. Epub 2017 Jul 17.

PMID:
28717852
9.

Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI.

Oncogene. 2017 Mar;36(11):1559-1572. doi: 10.1038/onc.2016.324. Epub 2016 Sep 26.

PMID:
27669433
10.

Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer.

Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, Williams AJ, Cote RJ, Lippman ME, Datar RH, El-Ashry D.

Cancer Res. 2015 Nov 15;75(22):4681-7. doi: 10.1158/0008-5472.CAN-15-1633. Epub 2015 Oct 15.

11.

Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.

Goka ET, Lippman ME.

Oncogene. 2015 Oct 16;34(42):5395-405. doi: 10.1038/onc.2014.468. Epub 2015 Feb 9.

12.

Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.

Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML.

J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju288. doi: 10.1093/jnci/dju288. Print 2014 Dec.

13.

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.

Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, Clarke J, Campion-Flora A, Rodrigues DN, Reis-Filho JS, Rae JM, Thomas D, Berry D, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2014 Nov;148(1):41-59. doi: 10.1007/s10549-014-3122-4. Epub 2014 Oct 1.

PMID:
25270120
14.

Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.

Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D.

Breast Cancer Res Treat. 2014 Apr;144(3):503-17. doi: 10.1007/s10549-014-2887-9. Epub 2014 Feb 25.

PMID:
24567196
15.

CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.

Dan T, Hewitt SM, Ohri N, Ly D, Soule BP, Smith SL, Matsuda K, Council C, Shankavaram U, Lippman ME, Mitchell JB, Camphausen K, Simone NL.

Breast Cancer Res Treat. 2014 Jan;143(1):11-8. doi: 10.1007/s10549-013-2758-9. Epub 2013 Nov 26.

PMID:
24276281
16.

Paget's disease of the nipple.

Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, Yepes MM, Lippman ME.

Breast Cancer Res Treat. 2013 Aug;141(1):1-12. doi: 10.1007/s10549-013-2661-4. Epub 2013 Aug 9. Review.

PMID:
23929251
17.

Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.

Sikora MJ, Strumba V, Lippman ME, Johnson MD, Rae JM.

Breast Cancer Res Treat. 2012 Aug;134(3):1027-39. doi: 10.1007/s10549-012-2032-6. Epub 2012 Mar 29.

18.

Rescue of tropomyosin deficiency in Drosophila and human cancer cells by synaptopodin reveals a role of tropomyosin α in RhoA stabilization.

Wong JS, Iorns E, Rheault MN, Ward TM, Rashmi P, Weber U, Lippman ME, Faul C, Mlodzik M, Mundel P.

EMBO J. 2012 Feb 15;31(4):1028-40. doi: 10.1038/emboj.2011.464. Epub 2011 Dec 13.

19.

Twenty-five year results of the national cancer institute randomized breast conservation trial.

Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, Lippman ME, Glatstein E, Swain SM, Danforth DN, Camphausen K.

Breast Cancer Res Treat. 2012 Feb;132(1):197-203. doi: 10.1007/s10549-011-1867-6. Epub 2011 Nov 24.

PMID:
22113254
20.

AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis.

Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, Bartelink H, Rooswinkel R, Lafleur V, Verheij M.

Radiat Oncol. 2009 Oct 23;4:47. doi: 10.1186/1748-717X-4-47.

21.

Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody.

Hnatyszyn HJ, Liu M, Hilger A, Herbert L, Gomez-Fernandez CR, Jorda M, Thomas D, Rae JM, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2010 Jul;122(2):371-80. doi: 10.1007/s10549-009-0584-x. Epub 2009 Oct 20.

PMID:
19842031
22.

Editorial: Cost-effective analyses in Breast Cancer Research and Treatment [corrected].

Lippman ME, Ethier S, Hayes DF.

Breast Cancer Res Treat. 2009 May;115(2):221-2. doi: 10.1007/s10549-009-0414-1. No abstract available. Erratum in: Breast Cancer Res Treat. doi: 10.1007/s10549-010-0743-0.

PMID:
19449205
23.

Anti-vascular therapy: a new approach to cancer treatment.

Hayes AJ, Li LY, Lippman ME.

West J Med. 2000 Jan;172(1):39-42. No abstract available.

24.
25.

The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM.

Breast Cancer Res Treat. 2009 May;115(2):289-96. doi: 10.1007/s10549-008-0080-8. Epub 2008 Jun 4.

26.

A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival.

Yu J, Yu J, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, Lippman ME.

Neoplasia. 2008 Jan;10(1):79-88.

27.

A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up.

Walshe JM, Berman AW, Vatas U, Steinberg SM, Anderson WF, Lippman ME, Swain SM.

Breast Cancer Res Treat. 2007 Jun;103(2):177-83. Epub 2006 Oct 13.

PMID:
17039267
28.

Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.

Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.

Clin Cancer Res. 2006 Sep 1;12(17):5242-7.

29.

New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK.

Hayes DF, Ethier S, Lippman ME.

Breast Cancer Res Treat. 2006 Nov;100(2):237-8. Epub 2006 Jun 14. No abstract available.

PMID:
16773436
30.

Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors.

Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan AM, Lippman ME, Rae JM.

Genome Biol. 2006;7(4):R28. Epub 2006 Apr 7.

31.

GREB1 is a novel androgen-regulated gene required for prostate cancer growth.

Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME.

Prostate. 2006 Jun 1;66(8):886-94.

PMID:
16496412
32.

GREB 1 is a critical regulator of hormone dependent breast cancer growth.

Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME.

Breast Cancer Res Treat. 2005 Jul;92(2):141-9.

33.

Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.

Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, Van't Veer L, Wicha M.

Breast Cancer Res Treat. 2005 Mar;90(1):1-3. No abstract available.

34.

(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.

Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, Chen J, Rae JM, Lawrence T, Lippman ME.

Mol Cancer Ther. 2005 Feb;4(2):197-205.

35.

Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.

Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM.

J Clin Oncol. 2004 Oct 15;22(20):4067-74.

PMID:
15483018
36.

EGFR and EGFRvIII expression in primary breast cancer and cell lines.

Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME.

Breast Cancer Res Treat. 2004 Sep;87(1):87-95.

37.

Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.

Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, Wang R, Fang X, Guo R, Zhang M, Lippman ME, Yang D, Wang S.

J Med Chem. 2004 May 6;47(10):2430-40.

PMID:
15115387
38.

Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors.

Rae JM, Lippman ME.

Breast Cancer Res Treat. 2004 Jan;83(2):99-107.

39.

Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice.

Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kern FG, Stetler-Stevenson WG, Lippman ME, Thompson EW.

Cancer Res. 2004 Jan 15;64(2):652-8.

40.

Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.

Wang S, Yang D, Lippman ME.

Semin Oncol. 2003 Oct;30(5 Suppl 16):133-42. Review.

PMID:
14613034
41.

Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, Menard C, Lippman ME, Lichter AS, Altemus RM.

Cancer. 2003 Aug 15;98(4):697-702.

42.

Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.

Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD.

Pharmacogenetics. 2003 Aug;13(8):501-7.

PMID:
12893988
43.

Acceptability of diagnostic tests for breast cancer.

Liang W, Lawrence WF, Burnett CB, Hwang YT, Freedman M, Trock BJ, Mandelblatt JS, Lippman ME.

Breast Cancer Res Treat. 2003 May;79(2):199-206.

44.

Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.

Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM.

Cancer Res. 2003 Jan 1;63(1):132-9.

45.

Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring.

Hilakivi-Clarke L, Cho E, Cabanes A, DeAssis S, Olivo S, Helferich W, Lippman ME, Clarke R.

Clin Cancer Res. 2002 Nov;8(11):3601-10.

46.

Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses.

Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y, Clarke R.

Clin Cancer Res. 2002 May;8(5):1155-66.

47.

Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.

Meehan KR, Slack R, Gehan E, Herscowitz HB, Areman EM, Ebadi M, Cairo MS, Lippman ME.

J Hematother Stem Cell Res. 2002 Apr;11(2):415-21.

PMID:
11983113
48.
49.

Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells.

Yang X, Wei LL, Tang C, Slack R, Mueller S, Lippman ME.

Cancer Res. 2001 Jul 1;61(13):5284-8.

50.

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR.

J Clin Oncol. 2001 Jun 15;19(12):3111-6. Erratum in: J Clin Oncol 2002 Mar 1;20(5):1430.

PMID:
11408508

Supplemental Content

Loading ...
Support Center